Aastrom Biosciences' CFO to Present at Noble Financial Group Small Cap Conference
September 21 2006 - 4:00PM
PR Newswire (US)
ANN ARBOR, Mich., Sept. 21 /PRNewswire-FirstCall/ -- Aastrom
Biosciences, Inc. (NASDAQ:ASTM) today announced that Gerald D.
Brennan, Jr., Vice President Administrative & Financial
Operations and Chief Financial Officer, will present at the Noble
Financial Group Small Cap Conference. The conference will be held
September 26-28th at the Ballantyne Golf & Spa Resort in
Charlotte, NC. Mr. Brennan will present at 4:15 p.m. (Eastern
Time), on Tuesday, September 26th. (Logo:
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO ) A live
webcast of Aastrom's presentation can be accessed by logging onto
the web at
http://hosted.mediasite.com/hosted/viewer/?peid=9710a2b9-4b6c-4d20-
bdd9-a80b28a62647 (copy and paste link into your browser). A replay
of the presentation will be archived until the conclusion of the
conference on September 28th, at the same site. For more
information, please visit the conference website at
http://www.ontrack06.com/ . About Aastrom Biosciences, Inc. Aastrom
Biosciences, Inc. (NASDAQ:ASTM) is developing autologous cell
products for the repair or regeneration of multiple human tissues,
based on its proprietary Tissue Repair Cell (TRC) technology.
Aastrom's TRC-based products are a unique cell mixture containing
stromal, stem and progenitor cell populations, produced outside the
body from a small amount of bone marrow taken from the patient.
TRC-based products have been used in over 225 patients, and are
currently in clinical trials for bone regeneration (long bone
fractures and spine fusion) and vascular regeneration (critical
limb ischemia) applications. The Company has reported positive
interim clinical trial results for TRCs suggesting both the
clinical safety and the ability of TRCs to induce tissue
regeneration in long bone fractures and jaw bone reconstruction.
Recently, the Company's proprietary TRCs received an Orphan Drug
Designation from the U.S. Food and Drug Administration (FDA) for
use in the treatment of osteonecrosis of the femoral head. In
addition, Aastrom is developing plans for a TRC-based therapy for
cardiac regeneration. For more information, visit Aastrom's website
at http://www.aastrom.com/ . This document contains forward-looking
statements, including without limitation, statements regarding
product development objectives, market development plans, and
potential advantages and applications of Tissue Repair Cells, which
involve certain risks and uncertainties. The forward-looking
statements are also identified through use of the words "plans,"
and other words of similar meaning. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the results obtained from clinical trial
activities, regulatory approval requirements, and the availability
of resources. These and other significant factors are discussed in
greater detail in Aastrom's Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission. CONTACTS: Kris
M. Maly Cameron Associates Investor Relations Department Kevin
McGrath Aastrom Biosciences, Inc. Phone: (212) 245-4577 Phone:
(734) 930-5777 Deanne Eagle (Media) Phone: (212) 554-5463
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO
http://photoarchive.ap.org/ DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly, Investor Relations Department of Aastrom
Biosciences, Inc., +1-734-930-5777; or Kevin McGrath,
+1-212-245-4577, or Deanne Eagle (Media), +1-212-554-5463, both of
Cameron Associates Web site: http://www.aastrom.com/
http://www.ontrack06.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024